NanoViricides, Inc. (OTC BB: NNVC) (the “Company") announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency (EMA) for DengueCide™, its drug candidate for the treatment of dengue and dengue hemorrhagic fever. EMA…
Source: NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide
Monday, July 1, 2013
NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment